Oritavancin pharmacokinetics and bone penetration in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6501-6505

  Lehoux, Dario ^a   Ostiguy, Valerie ^a   Cadieux, Cordelia ^a   Malouin, Mireille ^a   Belanger, Odette ^a   Far, Adel Rafai ^a   Parr, Thomas R ^a  

^a The Medicines Company   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ORITAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MATRIX; BONE TISSUE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TOLERABILITY; EXPERIMENTAL RABBIT; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BLOOD; BONE MARROW; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; RABBIT; TIBIA; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BONE MARROW; GLYCOPEPTIDES; INJECTIONS, INTRAVENOUS; MALE; RABBITS; TIBIA;

EID: 84942881471     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00981-15     Document Type: Article

References (30)

1. The Medicines Company. 2014. Orbactiv (oritavancin) for injection, for intravenous use. The Medicines Company, Parsippany, NJ. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206334s000lbl.pdf.
2. Zhanel GG, Schweizer F, Karlowsky JA. 2012. Oritavancin: mechanism of action. Clin Infect Dis 54(Suppl 3):S214-S219. http://dx.doi.org/10.1093/cid/cir920.
3. Poulakou G, Giamarellou H. 2008. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs 17:225-243. http://dx.doi.org/10.1517/13543784.17.2.225.
4. Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. 2015. Population pharmacokinetic analysis for a single 1, 200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother 59:3365-3372. http://dx.doi.org/10.1128/AAC.00176-15.
5. Wright JA, Nair SP. 2009. Interaction of staphylococci with bone. Int J Med Microbiol 300:193-204. http://dx.doi.org/10.1016/j.ijmm.2009.10.003.
6. Reizner W, Hunter JG, O'Malley NT, Southgate RD, Schwarz EM, Kates SL. 2014. A systematic review of animal models for Staphylococcus aureus osteomyelitis. Eur Cell Mater 27:196-212.
7. Nixon M, Jackson B, Varghese P, Jenkins D, Taylor G. 2006. Methicillinresistant Staphylococcus aureus on orthopaedic wards: incidence, spread, mortality, cost and control. J Bone Joint Surg Br 88:812-817. http://dx.doi.org/10.1302/0301-620X.88B6.17544.
8. Lee BY, Wiringa AE, Bailey RR, Lewis GJ, Feura J, Muder RR. 2010. Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis. Vaccine 28:2465-2471. http://dx.doi.org/10.1016/j.vaccine.2009.12.075.
9. Karlowsky JA, Walkty AJ, Baxter MR, Adam HJ, Zhanel GG. 2014. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagn Microbiol Infect Dis 80:311-315. http://dx.doi.org/10.1016/j.diagmicrobio.2014.09.003.
10. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. 2015. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and U. S. hospitals (2010-13). J Antimicrob Chemother 70:498-504. http://dx.doi.org/10.1093/jac/dku421.
11. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. 2014. Oritavancin activity against Staphylococcus aureus causing invasive infections in U. S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother 58:2921-2924. http://dx.doi.org/10.1128/AAC.02482-13.
12. Arhin FF, Draghi DC, Pillar CM, Parr TR, Jr, Moeck G, Sahm DF. 2009. Comparative in vitro activity profile of oritavancin against recent Grampositive clinical isolates. Antimicrob Agents Chemother 53:4762-4771. http://dx.doi.org/10.1128/AAC.00952-09.
13. Mendes RE, Farrell DJ, Sader HS, Jones RN. 2012. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 54(Suppl 3):S203-S213. http://dx.doi.org/10.1093/cid/cir923.
14. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. 1998. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 42:981-983.
15. Cabellos C, Fernández A, Maiques JM, Tubau F, Ardanuy C, Viladrich PF, Liñares J, Gudiol F. 2003. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 47:1907-1911. http://dx.doi.org/10.1128/AAC.47.6.1907-1911.2003.
16. Gerber J, Smirnov A, Wellmer A, Ragheb J, Prange J, Schütz E, Wettich K, Kalich S, Nau R. 2001. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 45:2169-2172. http://dx.doi.org/10.1128/AAC.45.7.2169-2172.2001.
17. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
18. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. 2012. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis 54(Suppl 3):S229-S232. http://dx.doi.org/10.1093/cid/cir921.
19. Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2014. Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation. Antimicrob Agents Chemother 58:2059-2066. http://dx.doi.org/10.1128/AAC.02475-13.
20. Arhin FF, Belley A, McKay G, Beaulieu S, Sarmiento I, Parr TR, Jr, Moeck G. 2010. Assessment of oritavancin serum protein binding across species. Antimicrob Agents Chemother 54:3481-3483. http://dx.doi.org/10.1128/AAC.00271-10.
21. Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR, Jr, Moeck G. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 52:1597-1603. http://dx.doi.org/10.1128/AAC.01513-07.
22. Arhin FF, Sarmiento I, Parr TR, Jr, Moeck G. 2008. Binding of oritavancin to surfaces impacts choice of vessels for oritavancin in vitro assays. Abstr 58th Annu Meet Can Soc Microbiol. Canadian Society of Microbiologists, Calgary, Canada.
23. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR, Jr. 2003. Pharmacodynamics of oritavancin (LY333328) in a neutropenicmouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 47:1700-1706. http://dx.doi.org/10.1128/AAC.47.5.1700-1706.2003.
24. Bélanger O, Rozborskaya O, Dietrich E, Malouin M, Ostiguy V, Laquerre K, Lehoux D, Rafai Far A, Parr TR, Jr. 2008. Quantitative determination and pharmacokinetics of oritavancin in rabbit serum and tibia, abstr P1061. 18th Eur Cong Clin Microbiol Infect Dis (ECCMID), 19 to 22 April 2008, Barcelona, Spain.
25. Saleh-Mghir A, Lefort A, Petegnief Y, Dautrey S, Vallois JM, Le Guludec D, Carbon C, Fantin B. 1999. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 43:115-120. http://dx.doi.org/10.1093/jac/43.suppl-1.115.
26. Lefort A, Saleh-Mghir A, Garry L, Carbon C, Fantin B. 2000. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 44:3017-3021. http://dx.doi.org/10.1128/AAC.44.11.3017-3021.2000.
27. Inman EL. 1987. Determination of vancomycin related substances by gradient high-performance liquid chromatography. J Chromatogr 410:363-372. http://dx.doi.org/10.1016/S0021-9673 (00) 90066-9.
28. Swoboda S, Helbig L, Kommerell M, Simank HG, Kees F, Geiss HK, Hoppe-Tichy T, Schroder K. 2009. Bone tissue and plasma concentrations of linezolid and vancomycin in rabbits with prosthesis-related infection due to MRSA. Pharmazie 64:407-409.
29. 14C]teicoplanin in experimental Staphylococcus aureus infection of joint prostheses. Antimicrob Agents Chemother 42:2830-2835.
30. 14C]dalbavancin to New Zealand White rabbits. Antimicrob Agents Chemother 51:3008-3010. http://dx.doi.org/10.1128/AAC.00020-07.